$KROS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Keros Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Keros Therapeutics, Inc.. Get notifications about new insider transactions in Keros Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.79 | 270 | 16,953 | 458,172 | 458.4 K to 458.2 K (-0.06 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.79 | 414 | 25,995 | 687,251 | 687.7 K to 687.3 K (-0.06 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | M | 0.48 | 1,000 | 480 | 102,211 | |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 68.05 | 2 | 136 | 0 | 2 to 0 (-100.00 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 66.19 | 295 | 19,526 | 2 | 297 to 2 (-99.33 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 65.35 | 216 | 14,116 | 297 | 513 to 297 (-42.11 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 64.17 | 312 | 20,021 | 513 | 825 to 513 (-37.82 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 63.10 | 175 | 11,043 | 825 | 1,000 to 825 (-17.50 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Buy | M | 0.48 | 1,000 | 480 | 1,000 | 0 to 1,000 |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 5,300 | 1,590 | 145,605 | |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 68.05 | 14 | 953 | 27,991 | 28 K to 28 K (-0.05 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 67.05 | 262 | 17,567 | 28,005 | 28.3 K to 28 K (-0.93 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 65.99 | 1,845 | 121,752 | 28,267 | 30.1 K to 28.3 K (-6.13 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 64.93 | 1,272 | 82,591 | 30,112 | 31.4 K to 30.1 K (-4.05 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 63.74 | 1,460 | 93,060 | 31,384 | 32.8 K to 31.4 K (-4.45 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 62.85 | 447 | 28,094 | 32,844 | 33.3 K to 32.8 K (-1.34 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 5,300 | 1,590 | 33,291 | 28 K to 33.3 K (+18.93 %) |
| Jan 12 2021 | KROS | Keros Therapeutics ... | Regnante Keith | Chief Financial Off ... | Option Exercise | A | 70.93 | 49,150 | 3,486,210 | 49,150 | |
| Jan 12 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | A | 70.93 | 42,250 | 2,996,793 | 42,250 | |
| Jan 12 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | A | 70.93 | 42,250 | 2,996,793 | 42,250 | |
| Jan 12 2021 | KROS | Keros Therapeutics ... | Seehra Jasbir | Chief Executive Off ... | Option Exercise | A | 70.93 | 127,200 | 9,022,296 | 127,200 | |
| Dec 21 2020 | KROS | Keros Therapeutics ... | GRAY MARY ANN | Director | Option Exercise | A | 82.74 | 16,587 | 1,372,408 | 16,587 | |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 6,000 | 300,000 | 155,262 | 149.3 K to 155.3 K (+4.02 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 14,400 | 720,000 | 1,228,326 | 1.2 M to 1.2 M (+1.19 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 12,966 | 648,300 | 1,122,768 | 1.1 M to 1.1 M (+1.17 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 26,634 | 1,331,700 | 2,288,151 | 2.3 M to 2.3 M (+1.18 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 50.00 | 6,000 | 300,000 | 155,262 | 149.3 K to 155.3 K (+4.02 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 50.00 | 14,400 | 720,000 | 1,228,326 | 1.2 M to 1.2 M (+1.19 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 50.00 | 12,966 | 648,300 | 1,122,768 | 1.1 M to 1.1 M (+1.17 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 50.00 | 26,634 | 1,331,700 | 2,288,151 | 2.3 M to 2.3 M (+1.18 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 50.00 | 6,000 | 300,000 | 155,262 | 149.3 K to 155.3 K (+4.02 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 50.00 | 14,400 | 720,000 | 1,228,326 | 1.2 M to 1.2 M (+1.19 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 50.00 | 12,966 | 648,300 | 1,122,768 | 1.1 M to 1.1 M (+1.17 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 50.00 | 26,634 | 1,331,700 | 2,288,151 | 2.3 M to 2.3 M (+1.18 %) |
| May 29 2020 | KROS | Keros Therapeutics ... | Farzan Nima | Director | Option Exercise | A | 28.74 | 8,500 | 244,290 | 8,500 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Option Exercise | C | 0.00 | 167,537 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Option Exercise | C | 0.00 | 343,270 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Option Exercise | C | 0.00 | 1,382,295 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Buy | P | 16.00 | 120,000 | 1,920,000 | 2,013,102 | 1.9 M to 2 M (+6.34 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Buy | C | 0.00 | 167,537 | 0 | 1,893,102 | 1.7 M to 1.9 M (+9.71 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Buy | C | 0.00 | 343,270 | 0 | 1,725,565 | 1.4 M to 1.7 M (+24.83 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Buy | C | 0.00 | 1,382,295 | 0 | 1,382,295 | 0 to 1.4 M |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Seehra Jasbir | Chief Executive Off ... | Option Exercise | C | 0.00 | 11,169 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Seehra Jasbir | Chief Executive Off ... | Buy | P | 16.00 | 20,000 | 320,000 | 243,856 | 223.9 K to 243.9 K (+8.93 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Seehra Jasbir | Chief Executive Off ... | Buy | C | 0.00 | 11,169 | 0 | 223,856 | 212.7 K to 223.9 K (+5.25 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 36,858 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 79,653 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 88,460 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 163,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 68,654 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 91,538 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 82,425 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 169,307 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 737,226 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 663,825 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 1,363,542 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 43,750 | 700,000 | 149,262 | 105.5 K to 149.3 K (+41.46 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 105,000 | 1,680,000 | 1,213,926 | 1.1 M to 1.2 M (+9.47 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 94,546 | 1,512,736 | 1,109,802 | 1 M to 1.1 M (+9.31 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 194,203 | 3,107,248 | 2,261,517 | 2.1 M to 2.3 M (+9.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 36,858 | 0 | 105,512 | 68.7 K to 105.5 K (+53.69 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 79,653 | 0 | 1,108,926 | 1 M to 1.1 M (+7.74 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 88,460 | 0 | 1,015,256 | 926.8 K to 1 M (+9.54 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 163,612 | 0 | 2,067,314 | 1.9 M to 2.1 M (+8.59 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 68,654 | 0 | 68,654 | 0 to 68.7 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 91,538 | 0 | 1,029,273 | 937.7 K to 1 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 82,425 | 0 | 926,796 | 844.4 K to 926.8 K (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 169,307 | 0 | 1,903,702 | 1.7 M to 1.9 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 737,226 | 0 | 937,735 | 200.5 K to 937.7 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 663,825 | 0 | 844,371 | 180.5 K to 844.4 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 1,363,542 | 0 | 1,734,395 | 370.9 K to 1.7 M (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 148,922 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 744,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | ORBIMED ADVISORS LLC | Director | Buy | P | 16.00 | 375,200 | 6,003,200 | 1,119,812 | 744.6 K to 1.1 M (+50.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | ORBIMED ADVISORS LLC | Director | Buy | C | 0.00 | 148,922 | 0 | 148,922 | 0 to 148.9 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | ORBIMED ADVISORS LLC | Director | Buy | C | 0.00 | 744,612 | 0 | 744,612 | 0 to 744.6 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 36,858 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 79,653 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 88,460 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 163,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 68,654 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 91,538 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 82,425 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 169,307 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 737,226 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 663,825 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 1,363,542 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 43,750 | 700,000 | 149,262 | 105.5 K to 149.3 K (+41.46 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 105,000 | 1,680,000 | 1,213,926 | 1.1 M to 1.2 M (+9.47 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 94,546 | 1,512,736 | 1,109,802 | 1 M to 1.1 M (+9.31 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 194,203 | 3,107,248 | 2,261,517 | 2.1 M to 2.3 M (+9.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 36,858 | 0 | 105,512 | 68.7 K to 105.5 K (+53.69 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 79,653 | 0 | 1,108,926 | 1 M to 1.1 M (+7.74 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 88,460 | 0 | 1,015,256 | 926.8 K to 1 M (+9.54 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 163,612 | 0 | 2,067,314 | 1.9 M to 2.1 M (+8.59 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 68,654 | 0 | 68,654 | 0 to 68.7 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 91,538 | 0 | 1,029,273 | 937.7 K to 1 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 82,425 | 0 | 926,796 | 844.4 K to 926.8 K (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 169,307 | 0 | 1,903,702 | 1.7 M to 1.9 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 737,226 | 0 | 937,735 | 200.5 K to 937.7 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 663,825 | 0 | 844,371 | 180.5 K to 844.4 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 1,363,542 | 0 | 1,734,395 | 370.9 K to 1.7 M (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Option Exercise | C | 0.00 | 167,537 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Option Exercise | C | 0.00 | 343,270 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Option Exercise | C | 0.00 | 1,382,295 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Buy | P | 16.00 | 120,000 | 1,920,000 | 2,013,102 | 1.9 M to 2 M (+6.34 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Buy | C | 0.00 | 167,537 | 0 | 1,893,102 | 1.7 M to 1.9 M (+9.71 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Buy | C | 0.00 | 343,270 | 0 | 1,725,565 | 1.4 M to 1.7 M (+24.83 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Buy | C | 0.00 | 1,382,295 | 0 | 1,382,295 | 0 to 1.4 M |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 44,676 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 67,015 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 137,308 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 205,962 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 184,305 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 276,459 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 44,676 | 0 | 458,442 | 413.8 K to 458.4 K (+10.80 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 67,015 | 0 | 687,665 | 620.7 K to 687.7 K (+10.80 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 137,308 | 0 | 413,766 | 276.5 K to 413.8 K (+49.67 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 205,962 | 0 | 620,650 | 414.7 K to 620.7 K (+49.67 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 184,305 | 0 | 276,458 | 92.2 K to 276.5 K (+200.00 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 276,459 | 0 | 414,688 | 138.2 K to 414.7 K (+200.00 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 36,858 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 79,653 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 88,460 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 163,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 68,654 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 91,538 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 82,425 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 169,307 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 737,226 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 663,825 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 1,363,542 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 16.00 | 43,750 | 700,000 | 149,262 | 105.5 K to 149.3 K (+41.46 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 16.00 | 105,000 | 1,680,000 | 1,213,926 | 1.1 M to 1.2 M (+9.47 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 16.00 | 94,546 | 1,512,736 | 1,109,802 | 1 M to 1.1 M (+9.31 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 16.00 | 194,203 | 3,107,248 | 2,261,517 | 2.1 M to 2.3 M (+9.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 36,858 | 0 | 105,512 | 68.7 K to 105.5 K (+53.69 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 79,653 | 0 | 1,108,926 | 1 M to 1.1 M (+7.74 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 88,460 | 0 | 1,015,256 | 926.8 K to 1 M (+9.54 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 163,612 | 0 | 2,067,314 | 1.9 M to 2.1 M (+8.59 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 68,654 | 0 | 68,654 | 0 to 68.7 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 91,538 | 0 | 1,029,273 | 937.7 K to 1 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 82,425 | 0 | 926,796 | 844.4 K to 926.8 K (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 169,307 | 0 | 1,903,702 | 1.7 M to 1.9 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 737,226 | 0 | 937,735 | 200.5 K to 937.7 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 663,825 | 0 | 844,371 | 180.5 K to 844.4 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 1,363,542 | 0 | 1,734,395 | 370.9 K to 1.7 M (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | GORDON CARL L | Director | Option Exercise | C | 0.00 | 148,922 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | GORDON CARL L | Director | Option Exercise | C | 0.00 | 744,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | GORDON CARL L | Director | Buy | P | 16.00 | 375,200 | 6,003,200 | 1,119,812 | 744.6 K to 1.1 M (+50.39 %) |